Blocking the activity of an essential protein to treat T-cell acute lymphoblastic leukaemia
Dr Maarten Hoogenkamp will continue his work into blocking the EAAT1 protein, which is crucial for the growth of T-cell acute lymphoblastic leukaemia.
Harnessing the immune system to treat Ewing sarcoma in the lungs
Dr Jonathan Fisher aims to create an 'off the shelf' version of immunotherapy to for hard-to-treat Ewing sarcoma.
Exploring how osteosarcoma cells spread and survive elsewhere in the body
Dr Olivier Pardo will investigate how osteosarcoma cells which escape into the bloodstream survive to spread elsewhere in the body.
Investigating the role of a PRMT5 in Ewing sarcoma and its potential as a target for treatment
Professor Clare Davies and Dr Susanne Gatz explore whether PRMT5 inhibitors could be an effective and kinder treatment for Ewing sarcoma.
Stopping the alpha - a potential new treatment approach for osteosarcoma
Professor Plevin and Dr Margaret Cunningham will investigate an enzyme that might play a role in osteosarcoma development, and see whether this could form the basis of a new type of treatment.
Exploring surrounding epigenetic influences in Ewing sarcoma
Dr Sara Sánchez Molina is investigating how a certain gene drives Ewing sarcoma in order to find a better way to treat it.
Exploring potential indicators of the likely course of disease: analysing blood samples from patients recruited to the rEECur clinical trial
Professor Martin McCabe aims to understand whether blood-based biomarkers could help predict Ewing sarcoma survival.
Understanding CaMK1D in diffuse large B cell lymphoma in children
Understanding how a protein affects the growth and development of lymphoma cells in order to build the foundations for safer and more effective treatments.
Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.